Nessa Carey

Neuroscience · Life Sciences

20h-index1.9kcitations64works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Genetic Neurodegenerative Diseases(18), Virus-based gene therapy research(9), CRISPR and Genetic Engineering(9), Epigenetics and DNA Methylation(7), Mitochondrial Function and Pathology(7)

Publications64 total

Supplementary Table S3 from Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets
2023Open Access
Supplementary Table S4 from Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets
2023Open Access
Supplementary Table S4 from Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets
2023Open Access
Supplementary Table S2 from Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets
2023Open Access
Supplementary Fig from Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets
2023Open Access
Supplementary Table S2 from Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets
2023Open Access
Supplementary Table S1 from Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets
2023Open Access
Supplementary Fig from Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets
2023Open Access
Supplementary Table S1 from Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets
2023Open Access
Supplementary Table S3 from Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets
2023Open Access
Supplementary Table S5 from Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets
2023Open Access
Supplementary Table S5 from Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets
2023Open Access
Data from Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets
2023Open Access
Data from Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets
2023Open Access
The Genome in Turmoil
2019
Non-CG DNA methylation is a biomarker for assessing endodermal differentiation capacity in pluripotent stem cells
Nature Communications·2016· 48 citedOpen Access
Junk DNA
Columbia University Press eBooks·2015· 43 cited
Epigenetics
Drug Discovery Today Technologies·2013
Epigenetics in action: Part 3: It runs in the family.
Natural history·2012
Epigenetics in action: Part 1 : Deciphering the link between nature and nurture.
Natural history·2012
page 1 of 4Next →

Frequent Co-authors

Keith Johnson(12), James M. Flanagan(7), Laurence Wild(7), Chris Boshoff(7), Juan M. Funes(6), Stephen E. Henderson(6), Maria Anvret(4), Janet T. Powell(4), Catherine Boucher(3), Stephanie King(3), Catherine Winchester(3), Jonathan D. Best(3), Alun H. Davies(3), Robert Dalziel(3), Martin Gosling(3), Maria Eriksson(3), Tor Ansved(3), Mark E.S. Bailey(2), Michael J. Siciliano(2), Tim J. Kemp(2)